Latest Discovery Laboratories Inc. Stories
WARRINGTON, Pa., June 7, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced it will be presenting neonatal AFECTAIR® data at the 11th European Congress on Pediatric and Neonatal Ventilation being held June 6 - 9, 2012 in Montreux, Switzerland. Though initially presented in the U.S., these data presentations mark the first introduction of the AFECTAIR...
WARRINGTON, Pa., May 9, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, reported that data from a preclinical study of SURFAXIN LS(TM) (lyophilized KL(4 )surfactant) was recently published in the May issue of Pediatric Research. The results of the study demonstrate that improvements in lung function following administration of SURFAXIN LS compares favorably to...
WARRINGTON, Pa., May 3, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today reports financial results for the first quarter ended March 31, 2012. The Company will host a conference call this morning at 10:00 AM ET. Conference call details are below. Key financial information includes: For the first quarter of 2012, the Company reported an operating loss of...
WARRINGTON, Pa., May 1, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO) today announced the presentation of a new pharmacoeconomic analysis demonstrating that the lower rate of reintubation previously reported in infants treated with SURFAXIN(®), when compared with infants treated with Curosurf(®) and Survanta(®), the current global market leading surfactants, also resulted in a potential hospital cost savings of $160,000 to $252,000 per 100 infants. The...
WARRINGTON, Pa., March 29, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today reports financial results for the fourth quarter ended December 31, 2011. The Company will host a conference call this morning at 10:00 AM ET. Conference call details are below. Important recent milestones include: On March 6, 2012, the United States Food and Drug Administration (FDA)...
VANCOUVER, British Columbia, March 8, 2012 /PRNewswire-Asia/ -- Insiderslab.com has issued insider trading reports and Equity Research for the following companies: Exxon Mobil (NYSE:XOM), American Eagle (NYSE:AEO), Discovery Laboratories (NASDAQ:DSCO), NVR (NYSE:NVR), Chesapeake Energy (NYSE:CHK), and Microsoft (NASDAQ:MSFT). (Logo: http://photos.prnewswire.com/prnh/20100419/HKM001LOGO ) (Read full report by clicking the link below, you may need to copy and paste the full link to your...
WARRINGTON, Pa., March 7, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, will hold a conference call for investors today at 10 a.m. EST to discuss its March 6th announcement that SURFAXIN (lucinactant) has been approved by the FDA for the prevention of Respiratory Distress Syndrome (RDS) in premature infants at high risk for RDS. SURFAXIN is the first FDA-approved...
WARRINGTON, Pa., March 6, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced that the United States Food and Drug Administration (FDA) has approved SURFAXIN (lucinactant) for the prevention of Respiratory Distress Syndrome (RDS) in premature infants at high risk for RDS. SURFAXIN is the first synthetic, peptide-containing surfactant approved for use...
WARRINGTON, Pa., Feb. 8, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced that it has entered into a definitive agreement with Lacey Manufacturing, a unit of Precision Engineered Products, LLC to manufacture and supply product for the commercial introduction of AFECTAIR®. AFECTAIR was recently cleared for commercialization in the United States and...
WARRINGTON, Pa., Feb. 2, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced AFECTAIR® is now registered with the Food and Drug Administration (FDA) and is cleared to be marketed in the United States. AFECTAIR is a proprietary patient interface technology that simplifies delivery of aerosolized medications to patients requiring ventilator support....
